Fluorine F 18 Flotufolastat

Phase 2Small molecule

Fluorine F 18 Flotufolastat is one of 37 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaRecruiting

Prostate CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

39 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Nubeqa

Bayer

Approved

2 2

Erleada

Johnson & Johnson

Approved

2 3

Ritalin

Novartis

Approved

1 4

Xtandi

Astellas

Approved

1 5

Farxiga

Jevtana

Balversa

Estrace

Lynparza

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

Phase 2Recruiting

Prostate Carcinoma

NCT07185165

Clinical

Trials by Indication[1]

Prostate Carcinoma1 trial

Eclipse: Flotufolastat F 18 to Determine Treatment Success Following Prostate Focal Therapy

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07185165·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluorine F 18 Flotufolastat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorine F 18 Flotufolastat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorine F 18 Flotufolastat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Fluorine F 18 Flotufolastat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News